点突变的鸡Ii基因和Ii-新城疫病毒融合基因表达特性研究
|
摘要
Ii链是一种非多态性的Ⅱ型跨膜蛋白，其中一个重要功能是确保新合成的MHCⅡ分子的胞内转运。MHCⅡ-Ii复合体的内体分选信号已被证明为Ii链胞浆尾部的两个独立的亮氨酸基元，即Leu~7/Ile~8和Pro~(15)/Met~(16)/Leu~(17)。鸡Ii链胞浆尾部含有Leu~8/Ile~9和Val~(17)/Leu~(18)两个基元，但基元周围氨基酸是否对内体定位功能发挥作用还未见报道。我们利用大引物PCR定点突变法，将鸡Ii链胞浆尾部两个基元及其基元周围氨基酸分别突变为丙氨酸(Ala)，然后连接到pEGFP-C1载体中，构建一系列突变体。利用脂质体Lipofectamine~(TM)2000介导的转染方法，将突变体转染到COS-7细胞，荧光显微镜下观察GFP-Ii融合蛋白的定位情况。结果显示，两个基元可以独立调控Ii分子的内化；突变Glu~3、Glu~4、Gln~5、Ile~9、Ser~(10)、Ser~(15)、Gly~(16)、Val~(17)或Pro~(19)时，融合蛋白均定位于细胞浆，Ii分子内化功能丧失；而突变Arg~6、Asp~7、Ser~(11)、Asp~(12)、G1y~(13)或Ser~(14)时，融合蛋白均定位于细胞内体，Ii分子内化功能保持。结果表明，鸡Ii链胞浆尾部两个亮氨基酸基元具有独立地内体定位信号功能，同时，两个基元功能的正确发挥需要周围氨基酸特定的空间结构支持。
各类动物Ii链的跨膜区是进化中最保守的部分。研究发现，跨膜区在Ii分子自身聚合成三聚体中发挥重要的作用，在缺乏胞外区的情况下，跨膜区可以使Ii有效聚合成三聚体状态。已证实人Ii链跨膜区Gln~47，Thr~49和Thr~50三个氨基酸对MHCII-Ii复合物的形成是必须的。我们应用大引物PCR突变法，将鸡Ii基因的Gln~47和Thr~(50)氨基酸突变，构建了C1-Q47A和C1-T50A重组质粒。同时，MHCⅡ分子的α链和β链被亚克隆到pEGFP-N1载体，构建了GFP-α、GFP-β重组质粒。我们将C1-Q47A或C1-T50A和GFP-α、GFP-β共转染COS-7细胞，利用Western blot和免疫共沉淀对鸡Ii链跨膜的功能进行初步探讨。结果表明，突变Ii链跨膜区Gln~(47)或Thr~(50)氨基酸后，MHCⅡ-Ii复合物的形成受限。
Ii链可以应用于构建Ii-抗原表位嵌合体。一些研究者用Ii链序列作为基本的框架，将CLIP区用CD4+T细胞抗原表位基因序列替代，将该嵌合基因插入真核表达载体，构建的嵌合体中的抗原表位能够有效地呈递给T细胞。关于鸡Ii分子CLIP替代的DNA疫苗目前没有研究报道，我们利用3轮重叠PCR将鸡Ii基因的CLIP区去除，此时恰好形成了一个HindⅢ酶切位点，再通过常规PCR扩增NDV的F343抗原表位基因，该基因片段长33个氨基酸，两段带有HindⅢ酶切位点。将F343基因通过单酶切连接入Ii分子内，构建了C1-Ii-F343内源性靶向抗原表位嵌合体DNA疫苗。同时，构建了C1-F343非靶向DNA疫苗作为对照。30只6-8周龄的雌性BALB/c小鼠随机分为5组，用内源性靶向DNA疫苗(C1-Ii-F343)和非靶向DNA疫苗(C1-F343)于股四头肌进行免疫,生理盐水、C1和C1-△CLIP作为研究对照。经过3次免疫后，取外周血对小鼠的体液免疫进行检测，免疫结果显示，只有C1-Ii-F343和C1-F343免疫组小鼠可以检测到针对F343抗原的特异性抗体，抗体滴度分别达到6400和1600，内源性靶向DNA疫苗组明显高于非靶向DNA疫苗组。构建抗原表位DNA替换鸡Ii分子的CLIP片段基因疫苗，为NDV的双靶向疫苗奠定实验基础。
The invariant chain (Ii) is a non-polymorphic type ? transmembrane protein. A major function of Ii is to ensure the targeting of newly synthesized MHC ? to the endocytic pathway, the endosomal sorting signal for newly synthesizedαβIi complexes were identified as two independent motifs residues at positions Leu~7/Ile~8 and Met~(16) /Leu~(17) in the Ii cytoplasmic tail. Two similar signals, Leu~8/Ile~9 and Val~(17) /Leu~(18), were found in the cytoplasmic tail of chicken Ii. But the functional properties of the amino acids around the two motifs are not reported in chicken Ii so far. Two motifs and the amino acids around the motif residues were mutated to Ala by PCR-based megaprimer method for site-directed mutagenesis and ligated to the vector pEGFP-C1, the recombinant plasmid constructed respectively. These mutants were transiently transfected into the COS cells by Lipofectamine~(TM)2000, and then located fusion proteins were observed in the fluorescent microscope. Two Leu-based motifs both independently mediate efficient sorting to the endocytic pathway. When mutated Glu~3, Glu~4, Gln~5, Iie~9, Ser~(10), Ser~(15), Gly~(16) or Val~(17) to Ala, the GFP were detected on the plasma membrane, While Arg~6, Asp~7, Ser~(11), Asp~(12), Gly~(13) or Ser~(14) were mutated to Ala, GFP were located in the intracellular vesicles. Our results thus confirm that the cytosolic tail of chicken Ii comprises two independent endosomal sorting signals that function in internalization and a functional Leu-based sorting signal requires specific geometrically neighboring residues.
The most conserved region of Ii is in the tranmembrane (TM) domain. It was reported that tranmembrane played an important role in Ii self-polymerizing to trimerization, even though absence cytoplasmic side of the membrane. It was confirmed that Gln~(47), Thr~(49) and Thr~(50) in the tranmembrane were pre-requisite in the form of MHCII-Ii. Gln~(47) and Thr~(50) of chicken Ii were mutated to Ala by PCR-based megaprimer method for site-directed mutagenesis and ligated to the vector pEGFP-Cl, the recombinant plasmid C1-Q47A and C1-T50A constructed respectively. The recombinant vector N1-MHCII-αand N1-MHCII-βwere constructed by inserting PCR products into the plasmid pEGFP-Nl. C1-Q47A(C1-T50A) and N1-MHCII-α, N1-MHCII-βwere co-transfected into the COS-7 cell strain, using Western blot and Immunoprecipitation to examined the function of Ii tranmembrane.
Ii was applied for constructing chimera gene containing antigen epitope. Ii as the basic framework would be used to substitute CLIP district for CD4+T cells epitope sequences, and the chimeric gene frangments were cloned into the eukaryotic expression vector. The construction of the chimera of epitope can be effectively presented to T cells. There is no research on the CLIP alternative DNA vaccine in chicken Ii, we used three overlapping PCR to remove the CLIP district of chicken Ii, at this time just formed a Hind? restriction site. And then by conventional PCR, NDV F343 epitope fragments were amplified with Hind? restriction sites, about 33 amino acids. F343 gene fragments were connected to the Ii by Hindlll and constructed the C1-Ii-F343 endogenous targeting epitopes chimeric gene vaccine. At the same time, construction of the C1-F343 gene vaccine is as for a non-targeting control. 30 6 to 8-week-old female BALB / C mice were divided into five groups targeted by endogenous gene vaccine (C1-Ii-F343) and non-targeting vaccine (C1-F343) in the quadriceps Immunization, saline, C1, and C1-△CLIP as a study control. After three times after immunization, blood from the humoral immunity in mice for testing, immunization results showed that only C1-Ii-F343 and C1-F343 immune mice can be detected for the F343-specific antigen antibody, antibody titers 6400 and 1600, respectively, within the target gene-derived vaccine was significantly higher than non-targeted vaccine group. Construction of epitope gene replacement chicken Ii CLIP fragment of the DNA vaccine was based on the two targeting experimental basis.
各类动物Ii链的跨膜区是进化中最保守的部分。研究发现，跨膜区在Ii分子自身聚合成三聚体中发挥重要的作用，在缺乏胞外区的情况下，跨膜区可以使Ii有效聚合成三聚体状态。已证实人Ii链跨膜区Gln~47，Thr~49和Thr~50三个氨基酸对MHCII-Ii复合物的形成是必须的。我们应用大引物PCR突变法，将鸡Ii基因的Gln~47和Thr~(50)氨基酸突变，构建了C1-Q47A和C1-T50A重组质粒。同时，MHCⅡ分子的α链和β链被亚克隆到pEGFP-N1载体，构建了GFP-α、GFP-β重组质粒。我们将C1-Q47A或C1-T50A和GFP-α、GFP-β共转染COS-7细胞，利用Western blot和免疫共沉淀对鸡Ii链跨膜的功能进行初步探讨。结果表明，突变Ii链跨膜区Gln~(47)或Thr~(50)氨基酸后，MHCⅡ-Ii复合物的形成受限。
Ii链可以应用于构建Ii-抗原表位嵌合体。一些研究者用Ii链序列作为基本的框架，将CLIP区用CD4+T细胞抗原表位基因序列替代，将该嵌合基因插入真核表达载体，构建的嵌合体中的抗原表位能够有效地呈递给T细胞。关于鸡Ii分子CLIP替代的DNA疫苗目前没有研究报道，我们利用3轮重叠PCR将鸡Ii基因的CLIP区去除，此时恰好形成了一个HindⅢ酶切位点，再通过常规PCR扩增NDV的F343抗原表位基因，该基因片段长33个氨基酸，两段带有HindⅢ酶切位点。将F343基因通过单酶切连接入Ii分子内，构建了C1-Ii-F343内源性靶向抗原表位嵌合体DNA疫苗。同时，构建了C1-F343非靶向DNA疫苗作为对照。30只6-8周龄的雌性BALB/c小鼠随机分为5组，用内源性靶向DNA疫苗(C1-Ii-F343)和非靶向DNA疫苗(C1-F343)于股四头肌进行免疫,生理盐水、C1和C1-△CLIP作为研究对照。经过3次免疫后，取外周血对小鼠的体液免疫进行检测，免疫结果显示，只有C1-Ii-F343和C1-F343免疫组小鼠可以检测到针对F343抗原的特异性抗体，抗体滴度分别达到6400和1600，内源性靶向DNA疫苗组明显高于非靶向DNA疫苗组。构建抗原表位DNA替换鸡Ii分子的CLIP片段基因疫苗，为NDV的双靶向疫苗奠定实验基础。
The invariant chain (Ii) is a non-polymorphic type ? transmembrane protein. A major function of Ii is to ensure the targeting of newly synthesized MHC ? to the endocytic pathway, the endosomal sorting signal for newly synthesizedαβIi complexes were identified as two independent motifs residues at positions Leu~7/Ile~8 and Met~(16) /Leu~(17) in the Ii cytoplasmic tail. Two similar signals, Leu~8/Ile~9 and Val~(17) /Leu~(18), were found in the cytoplasmic tail of chicken Ii. But the functional properties of the amino acids around the two motifs are not reported in chicken Ii so far. Two motifs and the amino acids around the motif residues were mutated to Ala by PCR-based megaprimer method for site-directed mutagenesis and ligated to the vector pEGFP-C1, the recombinant plasmid constructed respectively. These mutants were transiently transfected into the COS cells by Lipofectamine~(TM)2000, and then located fusion proteins were observed in the fluorescent microscope. Two Leu-based motifs both independently mediate efficient sorting to the endocytic pathway. When mutated Glu~3, Glu~4, Gln~5, Iie~9, Ser~(10), Ser~(15), Gly~(16) or Val~(17) to Ala, the GFP were detected on the plasma membrane, While Arg~6, Asp~7, Ser~(11), Asp~(12), Gly~(13) or Ser~(14) were mutated to Ala, GFP were located in the intracellular vesicles. Our results thus confirm that the cytosolic tail of chicken Ii comprises two independent endosomal sorting signals that function in internalization and a functional Leu-based sorting signal requires specific geometrically neighboring residues.
The most conserved region of Ii is in the tranmembrane (TM) domain. It was reported that tranmembrane played an important role in Ii self-polymerizing to trimerization, even though absence cytoplasmic side of the membrane. It was confirmed that Gln~(47), Thr~(49) and Thr~(50) in the tranmembrane were pre-requisite in the form of MHCII-Ii. Gln~(47) and Thr~(50) of chicken Ii were mutated to Ala by PCR-based megaprimer method for site-directed mutagenesis and ligated to the vector pEGFP-Cl, the recombinant plasmid C1-Q47A and C1-T50A constructed respectively. The recombinant vector N1-MHCII-αand N1-MHCII-βwere constructed by inserting PCR products into the plasmid pEGFP-Nl. C1-Q47A(C1-T50A) and N1-MHCII-α, N1-MHCII-βwere co-transfected into the COS-7 cell strain, using Western blot and Immunoprecipitation to examined the function of Ii tranmembrane.
Ii was applied for constructing chimera gene containing antigen epitope. Ii as the basic framework would be used to substitute CLIP district for CD4+T cells epitope sequences, and the chimeric gene frangments were cloned into the eukaryotic expression vector. The construction of the chimera of epitope can be effectively presented to T cells. There is no research on the CLIP alternative DNA vaccine in chicken Ii, we used three overlapping PCR to remove the CLIP district of chicken Ii, at this time just formed a Hind? restriction site. And then by conventional PCR, NDV F343 epitope fragments were amplified with Hind? restriction sites, about 33 amino acids. F343 gene fragments were connected to the Ii by Hindlll and constructed the C1-Ii-F343 endogenous targeting epitopes chimeric gene vaccine. At the same time, construction of the C1-F343 gene vaccine is as for a non-targeting control. 30 6 to 8-week-old female BALB / C mice were divided into five groups targeted by endogenous gene vaccine (C1-Ii-F343) and non-targeting vaccine (C1-F343) in the quadriceps Immunization, saline, C1, and C1-△CLIP as a study control. After three times after immunization, blood from the humoral immunity in mice for testing, immunization results showed that only C1-Ii-F343 and C1-F343 immune mice can be detected for the F343-specific antigen antibody, antibody titers 6400 and 1600, respectively, within the target gene-derived vaccine was significantly higher than non-targeted vaccine group. Construction of epitope gene replacement chicken Ii CLIP fragment of the DNA vaccine was based on the two targeting experimental basis.
引文
[1]J Lipp, B Dobberstein. Signal recognition paticle-dependent membrane insertion of mouse invariant chain: a membrain-spanning protein with a cytoplasmically exposed amine terminus [J]. Cell Biology, 1986,102: 2169-2175
[2]Claesson L, Peterson PA. Association of human gamma chain with classⅡtransplantation antigens during intracellular transport [J]. Biochemistry,1983,22:3206-3213
[3]肖雨龙，于益芝综述，曹雪涛审阅．恒定链胞浆尾部在MHCⅡ类分子递呈抗原中的作用研究进展[J]．国外医学免疫学分册，1999，22(3)：116-118
[4]W．E．保罗[美]编著，吴玉章等译．基础免疫学[M]．北京：科学出版社．2003，297-370
[5]Jones PP, Murphy DB, Hewgill D, et al. Detection of a common polypeptide chain in I-A and I-E subregion immunoprecipitates [J]. Immunochemistry, 1978, 16:51 - 60
[6]王巧巧综述，王福庆审阅．MHCⅡ分子的伴随蛋白-Ii链[J]．国外医学免疫学分册，1999，22:307-310
[7]Anderson M, Miller J. Invariant Chain Can Function as a Chaperone Protein for Class Ⅱ Major Histocompatibility Complex Molecules [J]. Proc Natl Acad Sci, 1992, 89:2282-2286.
[8]Kropshofer H, Vogt A, Hammerling G. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding [J]. Proc Natl Acad Sci, 1995, 92:8313-8317.
[9]Serwe M, Reuter G, Sponaas A, Koch S, Koch N. Both invariant chain isoforms Ii31 and Ii41 promote class Ⅱ antigen presentation [J]. Int Immunol, 1997, 9:983-991.
[10]Bikoff E, Huang L, Episkopou V, van Meerwijk J, Germain R, Robertson E. Defective major histocompatibility complex class Ⅱ assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression [J]. J Exp Med, 1993, 177:1699-1712.
[11]Wright RJ, Bikoff EK, Stockinger B. The Ii41 isoform of invariant chain mediates both positive and negative selection events in T-cell receptor transgenic mice [J]. Immunology, 1998,95:309-313.
[12]Shachar I, Flavell R. Requirement for Invariant Chain in B Cell Maturation and Function [J]. Science, 1996, 274:106-108.
[13]Matza D, Wolstein O, Dikstein R, Shachar I. Invariant chain induces B cell maturation by activating a TAF(Ⅱ)105-NF-kappa B-dependent transcription program[J].J Biol Chem,2001,276:27203-27206.
[14]Matza D,Lantner F,Bogoch Y,Flaishon L,Hershkoviz R,Shachar I.Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity[J].Proc Natl Acad Sci,2002,99:3018-3023.
[15]Matza D,Kerem A,Medvedovsky H,Lantner F,Shachar I.Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain[J].Immunity,2002,17:549-560.
[16]Vigna J,Smith K,Lutz C.Invariant chain association with MHC class I:preference for HLA class Ⅰ/beta 2-microglobulin heterodimers,specificity,and influence of the MHC peptide-binding groove[J].J Immunol,1996,157:4503-4510.
[17]Reber AJ,Turnquist HR,Thomas HJ,Lutz CT,Solheim JC.Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class Ⅰ molecules[J].Immunogenetics,2002,54:74-81.
[18]Burton JD,Ely S,Reddy PK,Stein R,Gold DV,Cardillo TM,Goldenberg DM.CD74 is expressed by multiple myeloma and is a promising target for therapy[J].Clin Cancer Res,2004,10:6606-6611.
[19]Rangel LB,Agarwal R,Sherman-Baust CA,Mello-Coelho V,Pizer ES,Ji H,Taub DD,Morin PJ.Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers[J].Cancer Biol Ther,2004,3:1021-1027.
[20]Chamuleau ME,Souwer Y,Van Ham SM,Zevenbergen A,Westers TM,Berkhof J,Meijer CJ,van de Loosdrecht AA,Ossenkoppele GJ.Class Ⅱ-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome[J].Cancer Res,2004,64:5546-5550.
[21]Young AN,Amin MB,Moreno CS,Lim SD,Cohen C,Petros JA,Marshall FF,Neish AS.Expression profiling of renal epithelial neoplasms:a method for tumor classification and discovery of diagnostic molecular markers[J].A M J Pathol,2001,158:1639-1635.
[22]Datta MW,Shahsafaei A,Nadler LM,Freeman GJ,Dorfman DM.Expression of MHC class Ⅱ-associated invariant chain(Ii;CD74)in thymic epithelial neoplasms[J].Appl Immunohistochem Mol Morphol,2000,8:210-215.
[23]Ansari AA.A possible role of the MHC-associated invariant chain in rheumatoid arthritis[J].Semin Arthritis Rheum,1993,23:193-197.
[24]Hess AD,Thoburn C,Chen W,Miura Y,Van der Wall E.The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self epitope from a tumor-associated antigen[J].Clin Immunol,2001,101:67-76.
[25]Van Tienhoven EA,ten Brink CT,van Bergen J,Koning F,van Eden W,Broeren CP.Induction of antigen specific CD4+ T cell responses by invariant chain based DNA vaccines[J].Vaccine,2001,19:1515-1519.
[26]Fujii S,Senju S,Chen YZ,Ando M,Matsushita S,Nishimura Y The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class Ⅱ pathway in L cells[J].Hum Immunol,1998,59:607-614.
[27]Xu M,Lu X,Kallinteris NL,Wang Y,Wu S,von Hofe E,Gulfo JV,Humphreys RE,Hillman GG.Immunotherapy of cancer by antisense inhibition of li protein,an immunoregulator of antigen selection by MHC class Ⅱ molecules[J].Curr Opin Mol Ther,2004,6:160-165.
[28]Yamamoto K,Floyd-Smith G,Francke U,et al.The gene encoding the la-associated invariant chain is located on chromosome 18 in the mouse[J].Immunogenetics,1985,21:83-90
[29]Collins T,Korman AJ,Wake CT,et al.Immune interferon activates multiple class Ⅱ major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts[J].Proc Natl Acad Sci,1984,81:4917-4921
[30]Collins T,Korman AJ,Wake CT,et al.Immune interferon activates multiple class Ⅱ major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts[J].Proc Natl Acad Sci,1984,81:4917-4921
[31]Cresswell P.Invariant chain structure and MHC class Ⅱ function[J].Cell,1996,84,505-507
[32]Fineschi B,Arneson L,Naujokas M,Miller J.Proteolysis of major histocompatibility complex class Ⅱ-associated invariant chain is regulated by the alternatively spliced gene product p41[J].Proc Natl Acad Sci,1995,92:10257-10261.
[33]Bevec T,Stoka V,Pungercic G,Dolenc I,Turk V.Major histocompatibility complex class Il-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L [J].J Exp Med,1996,183:1331-1338.
[34]O'Sullivan DM,Noonan D,Quaranta V.Four la invariant chain forms derive from a single gene by alternate splicing and alternate initiation of transcription/translation[J].J Exp Med,1987,166:444-460.
[35]Bakke O,Dobberstein B.MHC class Ⅱ-associated invariant chain contains a sorting signal for endosomal compartments[J].Cell,1990,63:707-716.
[36]Lotteau V,Teyton L,Peleraux A,Nilsson T,Karlsson L,Schmid SL,Quaranta V,Peterson PA.Intracellular transport of class Ⅱ MHC molecules directed by invariant chain[J].Nature,1990,348:600-605.
[37]Koch N,Harris AW.Differential expression of the invariant chain in mouse tumor cells:relationship to B lymphoid development[J].J Immunol,1984,132:12-15.
[38]Badve S,Deshpande C,Hua Z.Expression of invariant chain(CD74)and major histocompatibility complex(MHC)class Ⅱ antigen in the human fetus[J].J histochem cytochem,2002,50(4):473-482
[39]Layet C,Germain RN.Invariant chain promotes egress of poorly expressed,haplotype-mismatched class Ⅱ major histocompatibility complex AαAp dimmers from the endoplsmic reticulum/cis-Golgi compartment[J].Proc Natl Acad Sci,1991,88:2346-2350
[40]Koch N,Wong GH,Schrader JW.Ia antigens and associated invariant chain are induced simultaneously in lines of T-dependent mast cells by recombinant interferon-gamma[J].J Immunol,1984,132:1361-1369.
[41]Collins T,Korman AJ,Wake CT,Boss JM,Kappes DJ,Fiers W,Ault KA,Gimbrone MA,Jr.,Strominger JL,Pober JS.Immune interferon activates multiple class Ⅱ major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts[J].Proc Natl Acad Sci,1984,81:4917-4921.
[42]Anderson KS,Cresswell P.A role for calnexin(IP90)in the assembly of class Ⅱ MHC molecules[J].Embo J,1994,13:675-682.
[43]Arunachalam B,Cresswell P.Molecular requirements for the interaction of class Ⅱ major histocompatibility complex molecules and invariant chain with calnexin[J].J Biol Chem,1995,270:2784-2790.
[44]Neweomb JR.,Carboy NC,Cresswell P.Trimerie interactions of the invariant chain and its association with major histocompatibility complex class Ⅱ aipha beta dimmers[J].J Biol Chem 1996,271:24249-24256.
[45]Ashman JB,Miller J.A role for the transmembrane domain in the trimerization of the MHC class Ⅱ associated invariant chain[J].J Immunol,1999,163:2704-2712.
[46]Pieters J.MHC class Ⅱ restricted antigen presentation[J].Curr Opin Immunol,1997,9:89-96.
[47]Bertolino P,Rabourdin-Combe C.The MHC class Ⅱ-associated invariant chain:a molecule with multiple roles in MHC class Ⅱ biosynthesis and antigen presentation to CD4+ T cells[J].Crit Rev Immunol,1996,16:359-379.
[48]Machamer CE,Cresswell P.Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens[J].J Immunol 1982,129:2564-2569.
[49]Warmerdam PA,Long EO,Roche PA.Isoforms of the invariant chain regulate transport of MHC class Ⅱ molecules to antigen processing compartments[J].J Cell Biol,1996;133:281-291.
[50]Roche PA,Teletski CL,Stang E,Bakke O,Long EO.Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization[J].Proc Natl Acad Sci,1993,90:8581-8585.
[51]Anderson MS,Swier K,Arneson L,Miller J.Enhanced antigen presentation in the absence of the invariant chain endosomal localization signal[J].J Exp Med,1993,178:1959-1969.
[52]Genuardi M,Saunders GF.Localization of the HLA class Ⅱ-associated invariant chain gene to human chromosome band 5q32[J].Immunogenetics,1988,28:53-56.
[53]Bangia N,Watts TH.Evidence for invariant chain 85-101(CLIP)binding in the antigen-binding site of MHC class Ⅱ molecules[J].Int Immunol,1995,7:1585-1591.
[54]Kageyama T,Yonezawa S,Ichinose M,Miki K,Moriyama A.Potential sites for processing of the human invariant chain by cathepsins D and E[J].Biochem Biophys Res Commun,1996,223:549-553.
[55]Morton PA,Zacheis ML,Giacoletto KS,Manning JA,Schwartz BD.Delivery of nascent MHC class Ⅱ-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells[J].J Immunol,1995,154:137-150.
[56]Vogt AB,Stern LJ,Amshoff C,Dobberstein B,Hammerling GJ,Kropshofer H.Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR[J].J Immunol,1995,155:4757-4765.
[57]Stumptner P,Benaroch P.Interaction of MHC class Ⅱ molecules with the invariant chain:role of the invariant chain(81-90)region[J].Embo J,1997,16:5807-5818.
[58]Lindstedt R,Liljedahl M,Peleraux A,Peterson PA,Karlsson L.The MHC class Ⅱ molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif[J].Immunity,1995,3:561-572.
[59]Marks MS,Roche PA,van Donselaar E,Woodruff L,Peters PJ,and Bonifacino JS.A lysosomal targeting signal in the cytoplasmic tail of the beta chain directs HLA-DM to MHC class Ⅱ compartments[J].J Cell Biol 1995;131:351-369.
[60]Copier J,Kleijmeer MJ,Ponnambalam S,Oorschot V,Potter P,Trowsdale J,Kelly A.Targeting signal and subcellular compartments involved in the intracellular trafficking of HLA-DMB[J].J Immunol 1996,157:1017-1027.
[61]Pieters J,Bakke O,Dobberstein B.The MHC class Ⅱ-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail[J].J Cell Sci,1993;106:831-846
[62]Odozizzi CG,Trowbridge IS,Xue L,Hopkins CR,et al.Sorting signals in the MHC class Ⅱ invariant chain cytoplasmic tail and transmembrane region determine trafficking to an eddocytic processing compartment[J].J Cell Biol,1994,126:317-330
[63]Warmerden PA,Long EO,Roche PA.Isoforms of the invariant chain regulate transport of MHV Ⅱ molecules to antigen processing compartments[J].J Cell Biol,1996,133:281-291
[64]Zhong G,Romaqnoli P,Germain RN.Related leucine-based cytoplasmic targeting signals in invariant chain and major histocompatibility complex class Ⅱ molecules control endocytid presentation of distinct determinants in a single protein[J].J Exp Med,1997,185:429-438
[65]Andrea Motta,Bj(?)rn Bremnes.Structure-Activity Relationship of the Leucine-based Sorting Motifs in the Cytosolic Tail of the Major Histocompatibility Complex-associated Invariant Chain[J].Biological chemistry,1995,270:27165-27171
[66]Simonsen A,Stang E,Bremnes B,et al.Sorting of MHC class Ⅱ molecules and the associated invariant chain(Ii)in polarized MDCK cells[J].J Cell Sci,1997,110:597-609
[67]Chervonsky A,Gordon L,Sant AJ.A segment of the MHC class Ⅱ beta chain plays a critical in targeting class Ⅱ molecules to the endocytic pathway[J].Im Immunol,1994;937-953
[68]Smiley ST,Rudensky AY,Glimcher LH,et al.Truncation of the class Ⅱ beta-chain cytoplasmic domain influences the level of class Ⅱ/invariant chain-derived peptide complexes[J].Proc Natl Acad Sci,1996,93-241
[69]Zhong Jiang,Minzhen Xu,Louis Savas,Invariant chain expression in colon neoplasms[J].Virchows Arch,1999,435:32-36
[70]Ostrand-Rosenberg S.Tumor immunotherapy:the tumor cell as an antigen-presenting cell[J].Curr Opin Immunol,1994,6:722-727.
[71]Ansari AA.A possible role of the MHC-associated invariant chain in rheumatoid arthritis[J].Semin Arthritis Rheum,1993;23:193-197.
[72]B．W．卡尔尼克．禽病学[M]．第十版．北京：中国农业出版社,1991．691-726
[73]殷震，刘景华．动物病毒学[M]．第二版．北京:科学出版社，1997．736-767
[74]贺东生，秦智锋，刘福安．新城疫病毒系统发育分析及强弱毒株的鉴别诊断[J]．动物医学进展，2000(2):27-31
[75]Pitt JJ, Da Silva EGerman JJ. Determination of the disulfide bond arrongement of Newcastle disease virus hemaggulutinon neuraminidase [J]. J Bio Chem.2000, 275(9):6469-6478.
[76]Collins MS, Strong I, Alexander D J. Evaluation of the molecular basis of pathogenicity of the variant Newcastle disease virus's termed'pigeon PMV - 1 viruses' [J]. Archives of Virology, 1994, 134(3-4): 403-411.
[77]Collins P L, Hightower L E, Ball L A. Transcriptional map for Newcastle disease virus [J]. Journal of Virology, 1980, 35: 682-693.
[78]Schaper U M, Fuller F J, W ard M D W, et al.Nucleotide sequence of the envolop protein genes of a high ly virulent neuotrop ic strains of New castle disease virus [J]. V irol, 1988, 165: 291-295.
[79]程相朝．新城疫病毒的基因组与结构蛋白特．征[J]．河南科技大学学，2004，24(1):20-25
[80]吴清民，李连业，郑浩等．新城疫抗原凝集价影响因素的探讨[J]．中国兽医杂志，2001(5):20-21
[81]常国权，高伟．鸡新城疫病毒的简易纯化与电镜检测[J]．中国兽医杂志，1995(11):7-8
[82]姜新，张萌，高明哲．用鸡红细胞提纯鸡新城疫病毒试验报告[J]．辽宁畜牧兽医，1991(3):7-9
[83]陈丽君，蔡学忠，刘秀梵．新城疫病毒分子生物学研究进展[J]．中国兽医杂志，1996(5):57-58
[84]王忠田，王泽霖，陈溥言等．新城疫病毒分子生物学最新研究进展[J]．动物医学进展，2002(2):33-36
[85]曹殿军，刘明，王莉林等．新城疫病毒F48E9株病毒糖蛋白的功能分析[J]．中国兽医学报，1996(6):534-539
[86]古长庆，金宁一，殷震．鸡新城疫病毒的F和HN蛋白在细胞融合中的作用[J]．预防兽医学进展，2001(1):5-7
[87]LoriW.McGinnes, TrudyG.Morrison. Role of carbohydrate processing and calnexin binding in the folding and activity of the HN protein of Newcastle disease virus [J]. Virus Research, 1998(53): 175-185
[88]Stone-Hulslander J, Morrison T.G. Detection of an interaction between the HN and F proteins in Newcastle disease virus-infected cells [J]. Journal of Virology, 1997(9): 6287-6295．
[89]梁荣，曹殿军，陈杰等．中国西北地区新城疫病毒分离株基因型与抗原性的关系[J]．中国兽医科技，2001(7):5-8
[90]曹殿军．新城疫诊断和流行病学的分子生物学时代[J]．中国家禽，2002(20):5-9
[91]吴艳涛，倪雪霞，万洪全等．我国部分地区不同动物来源新城疫病毒的分子流行病学研究[J]．病毒学报，2002(3):264-269
[92]Lomniczi B, Wehmann E, Herczeg J, et al. Newcastle disease outbreaks in recent years in Western Europe were caused by an Old (Ⅵ) and a novel genotype (Ⅶ) [J]. Archives of Virology, 1998(1)49-64.
[93]秦智锋，贺东生，吴红专等．华南地区三株新城疫地方强毒株的序列测定及其系统发育分析[J]．畜牧兽医学报，2003(1):67-71
[94]T.Morrison, A.Portner. The Paramyxovirus [J]. Plenum.New York, 1991, 347-375.
[95]Collin, JB.Bashiruddin, DJ.Alexander. Deduced acid sequences at the fusion protein cleavage site of Newcastle disease virus showing variation in antigenicity and pathogenicity [J]. Arch.Virol 1993, 128:363-370.
[96]DeLeeuw OS, Koch G, Hartog L et al. Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein [J] Gen Virol, 2005, 86(6):1759-69.
[97]Lori McGinnes, Theresa Sergei, Julie Reitter, et al. Carbohydrate Modifications of the NDV Fusion Protein Heptad Repeat Domains Influence Maturation and Fusion Activity [J]. Virology, 2001, 283: 332-342.
[98]Toyods T, Gotoh B, Sakaguchi T, et al. Identification of amino acid relevant three antigenic determinants on the fusion protein of NDV that are involved in fusion inhibition and neutralization [J]. Girol, 1988, 62: 4427-4430.
[99]Yusoff K, Nesbit M, McCarney H. Location of Neutralizing epitopes on the fusion proteins of Neweastlediseasse virus strain Beaudette C [J]. Gen.Virol, 1989, 70: 3105-3109.
[100]M.S.Collins, Sally Franklin, I.Strong, et al. Antigenic and phylogenetic studies on a variant Newcastle disease virus using anti-fusion protein monoclonal antibodies and partial sequencing of the fusion protein [J] gene. Avian Pathology 1998, 27, 90-96.
[101]Singh MO, Hang D. Recent adjuvantin veterinary vaccine. Adjuvant Int [J]. Parasitol, 2003, 33: 469-478.
[102]Nagy E, Oerbyshire JB, Dobos P, et al. Cloning and expression of cDNA in a baculovirus expression vectors system [J]. Virol, 1990, 176: 426-438.
[103]Rabu A, Tan WS, Kho CL, et al. Chimeric Newcastle disease virus nucleocapsid with parts of viral hemagglutinin-neuraminidase and fusion proteins [J]. Acta Virol, 2002 , 46(4): 211-217.
[104]SakaguchiM, Nakamura H, SonodaY, et al. Protection of chickens from Newcastel disease by vaccine by va cc ination with a linear plasmd DNA expressing the F protein of Newcastel disease virus [J]. Vaccine, 1998, 16 (16): 1469-1503.
[105]Emmanuel D, JacobY, Saran MF, et al. Lyssavirus glycoproteins Expressing immunologically potent foreign B cell and cytotoxic TLymphocyte epitopes as prototypes for multivalent vaccines [J]. J.Gene raL Virology, 1999, 80: 2343-2351.
[106]Wong HT, ChengS CS, ChenE WC, et al. Plasimds encoding foot and mouth disease virus VPI epitopes elicited immune responses in miceand swine and protected awine against viral infection [J]. Virology, 2000, 278: 27-35.
[107]Xiao Y, Lu Y, Chen YH Epitope-vaccine as aw [J] Immunology Leters, 2001, 77: 3-6.
[108]Fineschi B, Sakaguchi K, Appella E, Miller J. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain [J]. Immunol, 1996, 157:3211-3215
[109]Masashi niimi, Yutaka Nakai, Yoko Aida. Identification of Bovine Invariant Chain Gene by Nucleotide Sequencing [J]. Biophys Biiiochem Res Commun, 1996, 222: 7-12
[110]Yoder JA, Haire RN, Litman GW. Cloning of two zebrafish cDNAs that share domains with the MHC class Ⅱ-associated invariant chain [J]. Immunogenetics, 1999, 50:84-88
[111]Bremnes B, Rode M, Gedde-Dahl M, Nordeng TW, Jacobsen J, Ness SA, Bakke O. The MHC class Ⅱ-associated chicken invariant chain shares functional properties with its mammalian homologs [J]. Exp Cell Res, 2000, 259:360-369
[112]郭荣，邹萍，范华骅，崔磊，曹谊林，郑滨，高跞，高峰，陆华中．CⅡTA反义cDNA抑制Hela细胞表面MHCⅡ类抗原的表达[J]．中华血液学杂志，2003，24(12): 636-639．
[113]白俊，任军，韩月恒，韩者忆，许彦鸣．HBsAg与恒定链融合基因真核表达载体的构建及鉴定[J]．细胞与分子免疫学杂志．2004，20(6):727-728．
[114]高明，王海平，王燕宁等．BALB/c小鼠I-Adαβ链和恒定链Ii在COS-7细胞中的共定位．军事医学科学院院刊[J]．2004，6(28):505-507
[115]仲大莲．禽类Ii基因的克隆、表达及其功能的初步研究：[博士论文]．合肥：中国科学技术大学，2006
[116]Ann M.Dixon,Bradford J.Invariant Chain Transmembrane Domain Trimerization:A Step in MHC Class Ⅱ Assembly[J].Biochemistry,2006,45:5228-5234
[117]Sanderson S,Frauwirth K,Shastri N.Expression of endogenous peptide-major histocompatibility complex class Ⅱ complexes derived from invariant chain-antigen fusion proteins[J].Proc Natl Acad Sci,1995,92:7217-7221.
[118]Long EO.In search of a function for the invariant chain associated with Ia antigens[J].Surv Immunol Res,1985,4(1):27-34
[119]Tommy W,Nordeng.The Cytoplasmic Tail of Invariant Chain Regulates Endosome Fusion and Morphology[J].Molecular Biology of the Cell,2002,13:1846-1856
[120]J．萨姆布鲁克,DW．拉塞尔 等著[美](黄培堂等译)2002．分子克隆实验指南(第三版)[M]．北京：科学出版社。
[121]Pond L,Kuhn LA,Teyton L,Schutze MP,Tainer JA,Jackson MR,Peterson PA.A role for acidic residues in di-leucine motif-based targeting to the endocytic pathway[J].J Biol Chem,1995,270(34):19989-19997.
[122]Bremnes,B.,T.Madsen,M.Gedde-Dahl,and O.Bakke.An LI and VL motif in the cytoplasmic tail of the MHC-associated invariant chain mediate rapid internalization[J].Journal of Cell Science,1994,107:2021-2032.
[123]Bakke,O.,and B.Dobberstein.MHC class Ⅱ-associated invariant chain contains a sorting signal for edosomal compartments[J].Cell,1990,63:707-716.
[124]Jonathan B,Ashman.A Role for the Transmembrane Domain in the Trimerization of the MHC Class Ⅱ-Associated Invariant Chain[J].Journal of Immunology,1999,163:2704-2712.
[125]Barlow,D.J.,and J.M.Thornton.Helix geometry in proteins[J].J Mol.Biol.1988,201:601-619.
[126]Nagata T,Aoshi T,Suzuki M,Uchijima M,Kim YH,Yang Z,Koide Y.Induction of protective immunity to Listeria monocytogenes by immunization with plasmid DNA expressing a helper T-cell epitope that replaces the class Ⅱ-associated invariant chain peptide of the invariant chain[J].Infect Immun,2002,70:2676-2680.
[127]Nagata T,Higashi T,Aoshi T,Suzuki M,Uchijima M,Koide Y.Immunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain(Ii)induces specific helper T cells in vivo:the assessment of Ii p31 and p41 isoforms as vehicles for immunization[J].Vaccine,2001,20:105-114.
[128]Bonehill A,Heirman C,Tuyaerts S,Michiels A,Zhang Y,van der Bruggen P,Thielemans K.Efficient presentation of known HLA class Ⅱ-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class Ⅱ-associated invariant chain peptide[J].Cancer Res,2003,63:5587-5594.
[129]Gregers TF,Fleckenstein B,Vartdal F,Roepstorff P,Bakke O,Sandlie I.MHC class Ⅱ loading of high or low affinity peptides directed by Ii/peptide fusion constructs:implications for T cell activation[J].Int Immunol 2003,15:1291-1299.
[130]Van Bergen J,Schoenberger SP,Verreck F,Amons R,Offringa R,Koning F.Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP[J].Proc Natl Acad Sci USA 1997,94:7499-7502.
[2]Claesson L, Peterson PA. Association of human gamma chain with classⅡtransplantation antigens during intracellular transport [J]. Biochemistry,1983,22:3206-3213
[3]肖雨龙，于益芝综述，曹雪涛审阅．恒定链胞浆尾部在MHCⅡ类分子递呈抗原中的作用研究进展[J]．国外医学免疫学分册，1999，22(3)：116-118
[4]W．E．保罗[美]编著，吴玉章等译．基础免疫学[M]．北京：科学出版社．2003，297-370
[5]Jones PP, Murphy DB, Hewgill D, et al. Detection of a common polypeptide chain in I-A and I-E subregion immunoprecipitates [J]. Immunochemistry, 1978, 16:51 - 60
[6]王巧巧综述，王福庆审阅．MHCⅡ分子的伴随蛋白-Ii链[J]．国外医学免疫学分册，1999，22:307-310
[7]Anderson M, Miller J. Invariant Chain Can Function as a Chaperone Protein for Class Ⅱ Major Histocompatibility Complex Molecules [J]. Proc Natl Acad Sci, 1992, 89:2282-2286.
[8]Kropshofer H, Vogt A, Hammerling G. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding [J]. Proc Natl Acad Sci, 1995, 92:8313-8317.
[9]Serwe M, Reuter G, Sponaas A, Koch S, Koch N. Both invariant chain isoforms Ii31 and Ii41 promote class Ⅱ antigen presentation [J]. Int Immunol, 1997, 9:983-991.
[10]Bikoff E, Huang L, Episkopou V, van Meerwijk J, Germain R, Robertson E. Defective major histocompatibility complex class Ⅱ assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression [J]. J Exp Med, 1993, 177:1699-1712.
[11]Wright RJ, Bikoff EK, Stockinger B. The Ii41 isoform of invariant chain mediates both positive and negative selection events in T-cell receptor transgenic mice [J]. Immunology, 1998,95:309-313.
[12]Shachar I, Flavell R. Requirement for Invariant Chain in B Cell Maturation and Function [J]. Science, 1996, 274:106-108.
[13]Matza D, Wolstein O, Dikstein R, Shachar I. Invariant chain induces B cell maturation by activating a TAF(Ⅱ)105-NF-kappa B-dependent transcription program[J].J Biol Chem,2001,276:27203-27206.
[14]Matza D,Lantner F,Bogoch Y,Flaishon L,Hershkoviz R,Shachar I.Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity[J].Proc Natl Acad Sci,2002,99:3018-3023.
[15]Matza D,Kerem A,Medvedovsky H,Lantner F,Shachar I.Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain[J].Immunity,2002,17:549-560.
[16]Vigna J,Smith K,Lutz C.Invariant chain association with MHC class I:preference for HLA class Ⅰ/beta 2-microglobulin heterodimers,specificity,and influence of the MHC peptide-binding groove[J].J Immunol,1996,157:4503-4510.
[17]Reber AJ,Turnquist HR,Thomas HJ,Lutz CT,Solheim JC.Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class Ⅰ molecules[J].Immunogenetics,2002,54:74-81.
[18]Burton JD,Ely S,Reddy PK,Stein R,Gold DV,Cardillo TM,Goldenberg DM.CD74 is expressed by multiple myeloma and is a promising target for therapy[J].Clin Cancer Res,2004,10:6606-6611.
[19]Rangel LB,Agarwal R,Sherman-Baust CA,Mello-Coelho V,Pizer ES,Ji H,Taub DD,Morin PJ.Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers[J].Cancer Biol Ther,2004,3:1021-1027.
[20]Chamuleau ME,Souwer Y,Van Ham SM,Zevenbergen A,Westers TM,Berkhof J,Meijer CJ,van de Loosdrecht AA,Ossenkoppele GJ.Class Ⅱ-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome[J].Cancer Res,2004,64:5546-5550.
[21]Young AN,Amin MB,Moreno CS,Lim SD,Cohen C,Petros JA,Marshall FF,Neish AS.Expression profiling of renal epithelial neoplasms:a method for tumor classification and discovery of diagnostic molecular markers[J].A M J Pathol,2001,158:1639-1635.
[22]Datta MW,Shahsafaei A,Nadler LM,Freeman GJ,Dorfman DM.Expression of MHC class Ⅱ-associated invariant chain(Ii;CD74)in thymic epithelial neoplasms[J].Appl Immunohistochem Mol Morphol,2000,8:210-215.
[23]Ansari AA.A possible role of the MHC-associated invariant chain in rheumatoid arthritis[J].Semin Arthritis Rheum,1993,23:193-197.
[24]Hess AD,Thoburn C,Chen W,Miura Y,Van der Wall E.The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self epitope from a tumor-associated antigen[J].Clin Immunol,2001,101:67-76.
[25]Van Tienhoven EA,ten Brink CT,van Bergen J,Koning F,van Eden W,Broeren CP.Induction of antigen specific CD4+ T cell responses by invariant chain based DNA vaccines[J].Vaccine,2001,19:1515-1519.
[26]Fujii S,Senju S,Chen YZ,Ando M,Matsushita S,Nishimura Y The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class Ⅱ pathway in L cells[J].Hum Immunol,1998,59:607-614.
[27]Xu M,Lu X,Kallinteris NL,Wang Y,Wu S,von Hofe E,Gulfo JV,Humphreys RE,Hillman GG.Immunotherapy of cancer by antisense inhibition of li protein,an immunoregulator of antigen selection by MHC class Ⅱ molecules[J].Curr Opin Mol Ther,2004,6:160-165.
[28]Yamamoto K,Floyd-Smith G,Francke U,et al.The gene encoding the la-associated invariant chain is located on chromosome 18 in the mouse[J].Immunogenetics,1985,21:83-90
[29]Collins T,Korman AJ,Wake CT,et al.Immune interferon activates multiple class Ⅱ major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts[J].Proc Natl Acad Sci,1984,81:4917-4921
[30]Collins T,Korman AJ,Wake CT,et al.Immune interferon activates multiple class Ⅱ major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts[J].Proc Natl Acad Sci,1984,81:4917-4921
[31]Cresswell P.Invariant chain structure and MHC class Ⅱ function[J].Cell,1996,84,505-507
[32]Fineschi B,Arneson L,Naujokas M,Miller J.Proteolysis of major histocompatibility complex class Ⅱ-associated invariant chain is regulated by the alternatively spliced gene product p41[J].Proc Natl Acad Sci,1995,92:10257-10261.
[33]Bevec T,Stoka V,Pungercic G,Dolenc I,Turk V.Major histocompatibility complex class Il-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L [J].J Exp Med,1996,183:1331-1338.
[34]O'Sullivan DM,Noonan D,Quaranta V.Four la invariant chain forms derive from a single gene by alternate splicing and alternate initiation of transcription/translation[J].J Exp Med,1987,166:444-460.
[35]Bakke O,Dobberstein B.MHC class Ⅱ-associated invariant chain contains a sorting signal for endosomal compartments[J].Cell,1990,63:707-716.
[36]Lotteau V,Teyton L,Peleraux A,Nilsson T,Karlsson L,Schmid SL,Quaranta V,Peterson PA.Intracellular transport of class Ⅱ MHC molecules directed by invariant chain[J].Nature,1990,348:600-605.
[37]Koch N,Harris AW.Differential expression of the invariant chain in mouse tumor cells:relationship to B lymphoid development[J].J Immunol,1984,132:12-15.
[38]Badve S,Deshpande C,Hua Z.Expression of invariant chain(CD74)and major histocompatibility complex(MHC)class Ⅱ antigen in the human fetus[J].J histochem cytochem,2002,50(4):473-482
[39]Layet C,Germain RN.Invariant chain promotes egress of poorly expressed,haplotype-mismatched class Ⅱ major histocompatibility complex AαAp dimmers from the endoplsmic reticulum/cis-Golgi compartment[J].Proc Natl Acad Sci,1991,88:2346-2350
[40]Koch N,Wong GH,Schrader JW.Ia antigens and associated invariant chain are induced simultaneously in lines of T-dependent mast cells by recombinant interferon-gamma[J].J Immunol,1984,132:1361-1369.
[41]Collins T,Korman AJ,Wake CT,Boss JM,Kappes DJ,Fiers W,Ault KA,Gimbrone MA,Jr.,Strominger JL,Pober JS.Immune interferon activates multiple class Ⅱ major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts[J].Proc Natl Acad Sci,1984,81:4917-4921.
[42]Anderson KS,Cresswell P.A role for calnexin(IP90)in the assembly of class Ⅱ MHC molecules[J].Embo J,1994,13:675-682.
[43]Arunachalam B,Cresswell P.Molecular requirements for the interaction of class Ⅱ major histocompatibility complex molecules and invariant chain with calnexin[J].J Biol Chem,1995,270:2784-2790.
[44]Neweomb JR.,Carboy NC,Cresswell P.Trimerie interactions of the invariant chain and its association with major histocompatibility complex class Ⅱ aipha beta dimmers[J].J Biol Chem 1996,271:24249-24256.
[45]Ashman JB,Miller J.A role for the transmembrane domain in the trimerization of the MHC class Ⅱ associated invariant chain[J].J Immunol,1999,163:2704-2712.
[46]Pieters J.MHC class Ⅱ restricted antigen presentation[J].Curr Opin Immunol,1997,9:89-96.
[47]Bertolino P,Rabourdin-Combe C.The MHC class Ⅱ-associated invariant chain:a molecule with multiple roles in MHC class Ⅱ biosynthesis and antigen presentation to CD4+ T cells[J].Crit Rev Immunol,1996,16:359-379.
[48]Machamer CE,Cresswell P.Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens[J].J Immunol 1982,129:2564-2569.
[49]Warmerdam PA,Long EO,Roche PA.Isoforms of the invariant chain regulate transport of MHC class Ⅱ molecules to antigen processing compartments[J].J Cell Biol,1996;133:281-291.
[50]Roche PA,Teletski CL,Stang E,Bakke O,Long EO.Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization[J].Proc Natl Acad Sci,1993,90:8581-8585.
[51]Anderson MS,Swier K,Arneson L,Miller J.Enhanced antigen presentation in the absence of the invariant chain endosomal localization signal[J].J Exp Med,1993,178:1959-1969.
[52]Genuardi M,Saunders GF.Localization of the HLA class Ⅱ-associated invariant chain gene to human chromosome band 5q32[J].Immunogenetics,1988,28:53-56.
[53]Bangia N,Watts TH.Evidence for invariant chain 85-101(CLIP)binding in the antigen-binding site of MHC class Ⅱ molecules[J].Int Immunol,1995,7:1585-1591.
[54]Kageyama T,Yonezawa S,Ichinose M,Miki K,Moriyama A.Potential sites for processing of the human invariant chain by cathepsins D and E[J].Biochem Biophys Res Commun,1996,223:549-553.
[55]Morton PA,Zacheis ML,Giacoletto KS,Manning JA,Schwartz BD.Delivery of nascent MHC class Ⅱ-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells[J].J Immunol,1995,154:137-150.
[56]Vogt AB,Stern LJ,Amshoff C,Dobberstein B,Hammerling GJ,Kropshofer H.Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR[J].J Immunol,1995,155:4757-4765.
[57]Stumptner P,Benaroch P.Interaction of MHC class Ⅱ molecules with the invariant chain:role of the invariant chain(81-90)region[J].Embo J,1997,16:5807-5818.
[58]Lindstedt R,Liljedahl M,Peleraux A,Peterson PA,Karlsson L.The MHC class Ⅱ molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif[J].Immunity,1995,3:561-572.
[59]Marks MS,Roche PA,van Donselaar E,Woodruff L,Peters PJ,and Bonifacino JS.A lysosomal targeting signal in the cytoplasmic tail of the beta chain directs HLA-DM to MHC class Ⅱ compartments[J].J Cell Biol 1995;131:351-369.
[60]Copier J,Kleijmeer MJ,Ponnambalam S,Oorschot V,Potter P,Trowsdale J,Kelly A.Targeting signal and subcellular compartments involved in the intracellular trafficking of HLA-DMB[J].J Immunol 1996,157:1017-1027.
[61]Pieters J,Bakke O,Dobberstein B.The MHC class Ⅱ-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail[J].J Cell Sci,1993;106:831-846
[62]Odozizzi CG,Trowbridge IS,Xue L,Hopkins CR,et al.Sorting signals in the MHC class Ⅱ invariant chain cytoplasmic tail and transmembrane region determine trafficking to an eddocytic processing compartment[J].J Cell Biol,1994,126:317-330
[63]Warmerden PA,Long EO,Roche PA.Isoforms of the invariant chain regulate transport of MHV Ⅱ molecules to antigen processing compartments[J].J Cell Biol,1996,133:281-291
[64]Zhong G,Romaqnoli P,Germain RN.Related leucine-based cytoplasmic targeting signals in invariant chain and major histocompatibility complex class Ⅱ molecules control endocytid presentation of distinct determinants in a single protein[J].J Exp Med,1997,185:429-438
[65]Andrea Motta,Bj(?)rn Bremnes.Structure-Activity Relationship of the Leucine-based Sorting Motifs in the Cytosolic Tail of the Major Histocompatibility Complex-associated Invariant Chain[J].Biological chemistry,1995,270:27165-27171
[66]Simonsen A,Stang E,Bremnes B,et al.Sorting of MHC class Ⅱ molecules and the associated invariant chain(Ii)in polarized MDCK cells[J].J Cell Sci,1997,110:597-609
[67]Chervonsky A,Gordon L,Sant AJ.A segment of the MHC class Ⅱ beta chain plays a critical in targeting class Ⅱ molecules to the endocytic pathway[J].Im Immunol,1994;937-953
[68]Smiley ST,Rudensky AY,Glimcher LH,et al.Truncation of the class Ⅱ beta-chain cytoplasmic domain influences the level of class Ⅱ/invariant chain-derived peptide complexes[J].Proc Natl Acad Sci,1996,93-241
[69]Zhong Jiang,Minzhen Xu,Louis Savas,Invariant chain expression in colon neoplasms[J].Virchows Arch,1999,435:32-36
[70]Ostrand-Rosenberg S.Tumor immunotherapy:the tumor cell as an antigen-presenting cell[J].Curr Opin Immunol,1994,6:722-727.
[71]Ansari AA.A possible role of the MHC-associated invariant chain in rheumatoid arthritis[J].Semin Arthritis Rheum,1993;23:193-197.
[72]B．W．卡尔尼克．禽病学[M]．第十版．北京：中国农业出版社,1991．691-726
[73]殷震，刘景华．动物病毒学[M]．第二版．北京:科学出版社，1997．736-767
[74]贺东生，秦智锋，刘福安．新城疫病毒系统发育分析及强弱毒株的鉴别诊断[J]．动物医学进展，2000(2):27-31
[75]Pitt JJ, Da Silva EGerman JJ. Determination of the disulfide bond arrongement of Newcastle disease virus hemaggulutinon neuraminidase [J]. J Bio Chem.2000, 275(9):6469-6478.
[76]Collins MS, Strong I, Alexander D J. Evaluation of the molecular basis of pathogenicity of the variant Newcastle disease virus's termed'pigeon PMV - 1 viruses' [J]. Archives of Virology, 1994, 134(3-4): 403-411.
[77]Collins P L, Hightower L E, Ball L A. Transcriptional map for Newcastle disease virus [J]. Journal of Virology, 1980, 35: 682-693.
[78]Schaper U M, Fuller F J, W ard M D W, et al.Nucleotide sequence of the envolop protein genes of a high ly virulent neuotrop ic strains of New castle disease virus [J]. V irol, 1988, 165: 291-295.
[79]程相朝．新城疫病毒的基因组与结构蛋白特．征[J]．河南科技大学学，2004，24(1):20-25
[80]吴清民，李连业，郑浩等．新城疫抗原凝集价影响因素的探讨[J]．中国兽医杂志，2001(5):20-21
[81]常国权，高伟．鸡新城疫病毒的简易纯化与电镜检测[J]．中国兽医杂志，1995(11):7-8
[82]姜新，张萌，高明哲．用鸡红细胞提纯鸡新城疫病毒试验报告[J]．辽宁畜牧兽医，1991(3):7-9
[83]陈丽君，蔡学忠，刘秀梵．新城疫病毒分子生物学研究进展[J]．中国兽医杂志，1996(5):57-58
[84]王忠田，王泽霖，陈溥言等．新城疫病毒分子生物学最新研究进展[J]．动物医学进展，2002(2):33-36
[85]曹殿军，刘明，王莉林等．新城疫病毒F48E9株病毒糖蛋白的功能分析[J]．中国兽医学报，1996(6):534-539
[86]古长庆，金宁一，殷震．鸡新城疫病毒的F和HN蛋白在细胞融合中的作用[J]．预防兽医学进展，2001(1):5-7
[87]LoriW.McGinnes, TrudyG.Morrison. Role of carbohydrate processing and calnexin binding in the folding and activity of the HN protein of Newcastle disease virus [J]. Virus Research, 1998(53): 175-185
[88]Stone-Hulslander J, Morrison T.G. Detection of an interaction between the HN and F proteins in Newcastle disease virus-infected cells [J]. Journal of Virology, 1997(9): 6287-6295．
[89]梁荣，曹殿军，陈杰等．中国西北地区新城疫病毒分离株基因型与抗原性的关系[J]．中国兽医科技，2001(7):5-8
[90]曹殿军．新城疫诊断和流行病学的分子生物学时代[J]．中国家禽，2002(20):5-9
[91]吴艳涛，倪雪霞，万洪全等．我国部分地区不同动物来源新城疫病毒的分子流行病学研究[J]．病毒学报，2002(3):264-269
[92]Lomniczi B, Wehmann E, Herczeg J, et al. Newcastle disease outbreaks in recent years in Western Europe were caused by an Old (Ⅵ) and a novel genotype (Ⅶ) [J]. Archives of Virology, 1998(1)49-64.
[93]秦智锋，贺东生，吴红专等．华南地区三株新城疫地方强毒株的序列测定及其系统发育分析[J]．畜牧兽医学报，2003(1):67-71
[94]T.Morrison, A.Portner. The Paramyxovirus [J]. Plenum.New York, 1991, 347-375.
[95]Collin, JB.Bashiruddin, DJ.Alexander. Deduced acid sequences at the fusion protein cleavage site of Newcastle disease virus showing variation in antigenicity and pathogenicity [J]. Arch.Virol 1993, 128:363-370.
[96]DeLeeuw OS, Koch G, Hartog L et al. Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein [J] Gen Virol, 2005, 86(6):1759-69.
[97]Lori McGinnes, Theresa Sergei, Julie Reitter, et al. Carbohydrate Modifications of the NDV Fusion Protein Heptad Repeat Domains Influence Maturation and Fusion Activity [J]. Virology, 2001, 283: 332-342.
[98]Toyods T, Gotoh B, Sakaguchi T, et al. Identification of amino acid relevant three antigenic determinants on the fusion protein of NDV that are involved in fusion inhibition and neutralization [J]. Girol, 1988, 62: 4427-4430.
[99]Yusoff K, Nesbit M, McCarney H. Location of Neutralizing epitopes on the fusion proteins of Neweastlediseasse virus strain Beaudette C [J]. Gen.Virol, 1989, 70: 3105-3109.
[100]M.S.Collins, Sally Franklin, I.Strong, et al. Antigenic and phylogenetic studies on a variant Newcastle disease virus using anti-fusion protein monoclonal antibodies and partial sequencing of the fusion protein [J] gene. Avian Pathology 1998, 27, 90-96.
[101]Singh MO, Hang D. Recent adjuvantin veterinary vaccine. Adjuvant Int [J]. Parasitol, 2003, 33: 469-478.
[102]Nagy E, Oerbyshire JB, Dobos P, et al. Cloning and expression of cDNA in a baculovirus expression vectors system [J]. Virol, 1990, 176: 426-438.
[103]Rabu A, Tan WS, Kho CL, et al. Chimeric Newcastle disease virus nucleocapsid with parts of viral hemagglutinin-neuraminidase and fusion proteins [J]. Acta Virol, 2002 , 46(4): 211-217.
[104]SakaguchiM, Nakamura H, SonodaY, et al. Protection of chickens from Newcastel disease by vaccine by va cc ination with a linear plasmd DNA expressing the F protein of Newcastel disease virus [J]. Vaccine, 1998, 16 (16): 1469-1503.
[105]Emmanuel D, JacobY, Saran MF, et al. Lyssavirus glycoproteins Expressing immunologically potent foreign B cell and cytotoxic TLymphocyte epitopes as prototypes for multivalent vaccines [J]. J.Gene raL Virology, 1999, 80: 2343-2351.
[106]Wong HT, ChengS CS, ChenE WC, et al. Plasimds encoding foot and mouth disease virus VPI epitopes elicited immune responses in miceand swine and protected awine against viral infection [J]. Virology, 2000, 278: 27-35.
[107]Xiao Y, Lu Y, Chen YH Epitope-vaccine as aw [J] Immunology Leters, 2001, 77: 3-6.
[108]Fineschi B, Sakaguchi K, Appella E, Miller J. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain [J]. Immunol, 1996, 157:3211-3215
[109]Masashi niimi, Yutaka Nakai, Yoko Aida. Identification of Bovine Invariant Chain Gene by Nucleotide Sequencing [J]. Biophys Biiiochem Res Commun, 1996, 222: 7-12
[110]Yoder JA, Haire RN, Litman GW. Cloning of two zebrafish cDNAs that share domains with the MHC class Ⅱ-associated invariant chain [J]. Immunogenetics, 1999, 50:84-88
[111]Bremnes B, Rode M, Gedde-Dahl M, Nordeng TW, Jacobsen J, Ness SA, Bakke O. The MHC class Ⅱ-associated chicken invariant chain shares functional properties with its mammalian homologs [J]. Exp Cell Res, 2000, 259:360-369
[112]郭荣，邹萍，范华骅，崔磊，曹谊林，郑滨，高跞，高峰，陆华中．CⅡTA反义cDNA抑制Hela细胞表面MHCⅡ类抗原的表达[J]．中华血液学杂志，2003，24(12): 636-639．
[113]白俊，任军，韩月恒，韩者忆，许彦鸣．HBsAg与恒定链融合基因真核表达载体的构建及鉴定[J]．细胞与分子免疫学杂志．2004，20(6):727-728．
[114]高明，王海平，王燕宁等．BALB/c小鼠I-Adαβ链和恒定链Ii在COS-7细胞中的共定位．军事医学科学院院刊[J]．2004，6(28):505-507
[115]仲大莲．禽类Ii基因的克隆、表达及其功能的初步研究：[博士论文]．合肥：中国科学技术大学，2006
[116]Ann M.Dixon,Bradford J.Invariant Chain Transmembrane Domain Trimerization:A Step in MHC Class Ⅱ Assembly[J].Biochemistry,2006,45:5228-5234
[117]Sanderson S,Frauwirth K,Shastri N.Expression of endogenous peptide-major histocompatibility complex class Ⅱ complexes derived from invariant chain-antigen fusion proteins[J].Proc Natl Acad Sci,1995,92:7217-7221.
[118]Long EO.In search of a function for the invariant chain associated with Ia antigens[J].Surv Immunol Res,1985,4(1):27-34
[119]Tommy W,Nordeng.The Cytoplasmic Tail of Invariant Chain Regulates Endosome Fusion and Morphology[J].Molecular Biology of the Cell,2002,13:1846-1856
[120]J．萨姆布鲁克,DW．拉塞尔 等著[美](黄培堂等译)2002．分子克隆实验指南(第三版)[M]．北京：科学出版社。
[121]Pond L,Kuhn LA,Teyton L,Schutze MP,Tainer JA,Jackson MR,Peterson PA.A role for acidic residues in di-leucine motif-based targeting to the endocytic pathway[J].J Biol Chem,1995,270(34):19989-19997.
[122]Bremnes,B.,T.Madsen,M.Gedde-Dahl,and O.Bakke.An LI and VL motif in the cytoplasmic tail of the MHC-associated invariant chain mediate rapid internalization[J].Journal of Cell Science,1994,107:2021-2032.
[123]Bakke,O.,and B.Dobberstein.MHC class Ⅱ-associated invariant chain contains a sorting signal for edosomal compartments[J].Cell,1990,63:707-716.
[124]Jonathan B,Ashman.A Role for the Transmembrane Domain in the Trimerization of the MHC Class Ⅱ-Associated Invariant Chain[J].Journal of Immunology,1999,163:2704-2712.
[125]Barlow,D.J.,and J.M.Thornton.Helix geometry in proteins[J].J Mol.Biol.1988,201:601-619.
[126]Nagata T,Aoshi T,Suzuki M,Uchijima M,Kim YH,Yang Z,Koide Y.Induction of protective immunity to Listeria monocytogenes by immunization with plasmid DNA expressing a helper T-cell epitope that replaces the class Ⅱ-associated invariant chain peptide of the invariant chain[J].Infect Immun,2002,70:2676-2680.
[127]Nagata T,Higashi T,Aoshi T,Suzuki M,Uchijima M,Koide Y.Immunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain(Ii)induces specific helper T cells in vivo:the assessment of Ii p31 and p41 isoforms as vehicles for immunization[J].Vaccine,2001,20:105-114.
[128]Bonehill A,Heirman C,Tuyaerts S,Michiels A,Zhang Y,van der Bruggen P,Thielemans K.Efficient presentation of known HLA class Ⅱ-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class Ⅱ-associated invariant chain peptide[J].Cancer Res,2003,63:5587-5594.
[129]Gregers TF,Fleckenstein B,Vartdal F,Roepstorff P,Bakke O,Sandlie I.MHC class Ⅱ loading of high or low affinity peptides directed by Ii/peptide fusion constructs:implications for T cell activation[J].Int Immunol 2003,15:1291-1299.
[130]Van Bergen J,Schoenberger SP,Verreck F,Amons R,Offringa R,Koning F.Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP[J].Proc Natl Acad Sci USA 1997,94:7499-7502.